Rubicon Research, a company in the Pharmaceuticals industry, reported revenue of ₹576 crore and net profit of ₹90 crore for the September 2026 quarter.
Rubicon Research (NSE: RUBICON) closed at ₹1,718.70 on 20 Nov 2026, up 146.9% over the past year. Its market capitalisation is ₹28,451 crore and it trades at 87.6 times earnings.
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.